The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 25 January 2005, www.theannals.com, DOI 10.1345/aph.1E322.
 The Annals of Pharmacotherapy: Vol. 39, No. 3, pp. 523-526. DOI 10.1345/aph.1E322
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Backes, J. M
Right arrow Articles by Gibson, C. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Backes, J. M
Right arrow Articles by Gibson, C. A

DRUG INFORMATION ROUNDS

Effect of Lipid-Lowering Drug Therapy on Small-Dense Low-Density Lipoprotein

James M Backes, PharmD

Clinical Assistant Professor, Department of Pharmacy Practice, School of Pharmacy, University of Kansas, Kansas City, KS

Cheryl A Gibson, PhD

Research Associate Professor, Department of Internal Medicine, University of Kansas Medical Center, Kansas City

Reprints: Dr. Backes, Department of Pharmacy Practice, Lipid, Atherosclerosis, Metabolic and LDL-Apheresis Center, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160-7231, fax 913/588-2355, jbackes{at}kumc.edu

OBJECTIVE: To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C).

DATA SOURCES: Literature was obtained from MEDLINE (1989-September 2004) and references of selected articles. Key search terms included small-dense LDL-C and lipid-lowering drug therapy.

DATA SYNTHESIS: Statins, fibrates, and niacin have demonstrated favorable effects on sdLDL-C, especially among patients with mixed dyslipidemia or hypertriglyceridemia. These effects include a reduction of sdLDL-C and/or a shift to the larger, less atherogenic LDL-C.

CONCLUSIONS: Data suggest that statins, fibrates, and niacin are effective at reducing concentrations of sdLDL-C and possibly normalizing LDL-C subclasses.

Key Words: fibrates, low-density lipoprotein, niacin, small-dense, statins

Published Online, January 25, 2005. www.theannals.com, DOI 10.1345/aph.1E322




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.